Webinar: Role of Artificial Intelligence in Imaging of Osteoarthritis

Webinar: Role of Artificial Intelligence in Imaging of Osteoarthritis

Join Prof. Boesen, IAG’s Sn Theraputic Area Lead and Collaborators to Discuss the Role of AI in Imaging


Renowned A.I. expert, Prof. Mikael Boesen, MD, PhD will address OARSI community and drug development companies in upcoming webinar on the Role of Artificial Intelligence in Imaging.

London, 08 May 2024 – As the pharmaceutical industry continues to leverage cutting-edge technologies to enhance drug development processes, the integration of artificial intelligence (AI) in medical imaging emerges as a pivotal advancement.

In an effort to provide crucial insights tailored to Chief Medical Officers (CMOs) in drug development companies, Prof. Mikael Boesen, a distinguished expert in AI will deliver a talk during upcoming webinar titled

Role of Artificial Intelligence in Imaging: Implications for Drug Development.”

Scheduled for Wednesday, May 15, 2024, from 8:00 to 9:00 am ET, this webinar will serve as a platform for scientist and industry leaders to explore the transformative potential of AI in medical imaging within the context of drug development.

Mikael Boesen will offer strategic perspectives and actionable insights to empower dru development experts in navigating this evolving landscape.

About Prof. Mikael Boesen

With extensive experience in AI research and its intersection with healthcare, Prof. Mikael Boesen brings a wealth of knowledge to the discussion. Currently Professor of MSK Radiology & AI / Co-Founder RAIT.dk and CLIC-project.org, Dr. Boesen has played a pivotal role in advancing AI-driven solutions for medical imaging, with a focus on enhancing diagnostic accuracy, accelerating clinical trials, and optimizing treatment strategies.

During the webinar, participants can expect to gain insights into:

  • The role of AI in streamlining imaging processes in drug development
  • Leveraging AI-powered image analysis for enhanced efficacy and safety assessments in clinical trials
  • Strategies for integrating AI technologies into existing workflows to drive efficiency and innovation
  • Regulatory considerations and best practices for deploying AI solutions in drug development settings

The webinar will feature other speakers and collaborators, an interactive Q&A session, providing attendees with the opportunity to engage directly with the speakers and delve deeper into key topics and challenges.

We invite Chief Medical Officers, medical directors, and other senior executives involved in drug development and clinical research within pharmaceutical companies to follow-up with prof Boesen by emailing your questions to imaging.experts@ia-grp.com.

Registration for the webinar is now open: https://oarsi.org/education/oarsi-live-webinar-series

About Image Analysis Group (IAG)

Leading imaging Clinical Research Organization that combines medical and operational expertise with cutting-edge proprietary A.I. capabilities to power drug development, and to deliver the potential for companion diagnostic tool. IAG has been serving biotech and pharma clients globally since 2007, reliably supporting all aspects of phase I to III imaging trials across multiple indications. With a pioneering proven innovation strategy, we enhance the value and market potential of novel therapeutic assets, as demonstrated through successful pharmaceutical partnerships.

Learn more:  ww.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin